Juvonno Expands Its Open API Ecosystem, Giving Clinics Free Access to Powerful Integrations

More than 23 software developers have built AI-powered reception, reporting, and charting tools designed to transform how modern clinics operate.

WINNIPEG, MB, Sept. 4, 2026 /PRNewswire/ -- Juvonno's free Open API is creating a growing ecosystem of connected technologies for modern medical clinics. These advancements will give clinics greater freedom to choose specialized tools that complement their workflows and extend the capabilities of their practice management platform.

Juvonno, a clinic management software for growing allied health practices in Canada, the UK, and the USA, is expanding the possibilities available to its clients through the Juvonno Open API, a free resource for all Juvonno customers. Juvonno is working with more than 23 software developers building connected solutions, from AI-powered reception and reporting systems to charting tools.

The initiative is designed to give clinics greater flexibility to adopt technologies that fit their individual workflows while remaining connected to Juvonno. Through continuing to develop its API and support third-party developers, Juvonno is fostering an ecosystem in which clinics are not limited to a single set of tools or a one-size-fits-all approach.

Developers can build specialized solutions that enhance Juvonno's existing capabilities, while clinics can select technologies based on their operational needs, growth goals, and patient experience priorities. The result is a more flexible technological environment that can evolve alongside a clinic.

One example is Clinic OS, a complete clinic CRM developed by a clinic owner who operates a growing, multi-location organization. The platform offers full inbound lead management, connecting phone, SMS, email, and social media channels into a single intake system. An extensive AI backbone automates the new-patient process while providing clinic management teams with extensive reporting.

Juvonno's ongoing API development reflects a broader commitment to interoperability and innovation. It is proving to be a game-changer in the industry, giving clinics more control over their technology stack. Clinics can combine their core practice management platform with purpose-built technologies that help automate workflows, improve decision-making, and support sustainable growth.

About Juvonno: Juvonno is a comprehensive clinic management software built to help multidisciplinary clinics manage their day-to-day operations. Through continued platform development and its free Open API, Juvonno enables clinics to connect with innovative third-party technologies and build a technology ecosystem suited to their unique workflows and goals.

Media Contact

Terry Davison

+1 (866) 643-3041

SOURCE Juvonno

Share this article

Latest opening brings the Company's Florida dispensary count to 77 and 178 nationwide

STAMFORD, Conn., Sept. 4, 2026 /PRNewswire/ -- Curaleaf Holdings, Inc. (TSX: CURA) (OTCQX: CURLF) ("Curaleaf" or the "Company"), a leading international provider of consumer cannabis products, today announced the opening of Curaleaf Riverview, located at 10422 US Hwy 301 S, Riverview, FL 33578. With this opening, the Company's retail footprint grows to 77 dispensaries in Florida and 178 nationwide.

Located in the Tampa Bay area, Curaleaf Riverview is situated in a rapidly growing suburban community that has evolved from its rural roots along the Alafia River into a thriving hub for young professionals and businesses. With convenient access to Tampa, Brandon, Apollo Beach and the broader South Shore area, Riverview continues to see significant residential, retail and economic growth, making it an increasingly important community in the region. The dispensary features a broad range of products and brands for medical patients, including Curaleaf's Florida-exclusive Reef flower, Dark Heart ultra-premium flower, FIND flower, Anthem pre-rolls and the Select Briq 2 all-in-one vape.

"Our newest dispensary in the Tampa area is the latest of several openings in the state since the beginning of the year," said Boris Jordan, Chairman and CEO of Curaleaf. "This acceleration in the Florida market reflects our long-term strategy to strengthen our presence in this fast-growing medical cannabis market. As we continue to expand, we are focused on providing access to comprehensive, curated products offerings and patient-centered services that enhance the shopping experience."

A grand opening celebration will take place all day at Curaleaf Riverview on September 18 and 19, 2026, featuring brand activations, in-store promotions, and giveaways while supplies last. The dispensary will operate from Monday through Saturday from 9:00 A.M. to 8:30 P.M. ET, and 10:00 A.M. to 7:00 P.M. ET on Sundays.

For more information on Curaleaf's Florida dispensaries, products, and patient resources, please visit https://curaleaf.com/dispensary/florida.

About Curaleaf Holdings

Curaleaf Holdings, Inc. (TSX: CURA) (OTCQX: CURLF) ("Curaleaf") is a leading international provider of consumer products in cannabis with a mission to enhance lives by cultivating, sharing and celebrating the power of the plant. As a high-growth cannabis company known for quality, expertise and reliability, the Company and its brands, including Curaleaf, Select, Grassroots, Find, Dark Heart, and Anthem provide industry-leading service, product selection and accessibility across the medical and adult use markets. Curaleaf International is powered by a strong presence in all stages of the supply chain. Its unique distribution network throughout Europe, Canada and Australasia brings together pioneering science and research with cutting-edge cultivation, extraction and production. Curaleaf is listed on the Toronto Stock Exchange under the symbol CURA and trades on the OTCQX market under the symbol CURLF. For more information, please visit https://ir.curaleaf.com.

Forward Looking Statements

This media advisory contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward–looking statements or information. Generally, forward-looking statements and information may be identified by the use of forward-looking terminology such as "plans", "expects" or "proposed", "is expected", "intends", "anticipates", or "believes", or variations of such words and phrases, or by the use of words or phrases which state that certain actions, events or results may, could, would, or might occur or be achieved. More particularly and without limitation, this news release contains forward-looking statements and information concerning the opening of a dispensary in Riverview, Florida. Such forward-looking statements and information reflect management's current beliefs and are based on assumptions made by and information currently available to the company with respect to the matter described in this new release. Forward-looking statements involve risks and uncertainties, which are based on current expectations as of the date of this release and subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Additional information about these assumptions and uncertainties is discussed in the Company's Form 8-K dated August 5, 2026 together with the annual report on Form 10-K for the year ended December 31, 2025 and the quarterly report on Form 10-Q for the quarter ended March 31, 2026, attached as exhibits thereto, as well as the Form 10-Q for the quarter ended June 30, 2026, each of which documents have been filed on the Company's EDGAR profile at www.sec.gov/edgar and SEDAR+ profile at www.sedarplus.ca, and as described from time to time in documents filed by the Company with the U.S. Securities and Exchange Commission and the Canadian securities regulatory authorities. Forward-looking statements contained herein are made only as to the date of this press release and we undertake no obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required by law. We caution investors not to place considerable reliance on the forward-looking statements contained in this press release. The Toronto Stock Exchange has not reviewed, approved or disapproved the content of this news release.

Investor Contact:

Curaleaf Holdings, Inc.

Camilo Lyon, Chief Investment Officer

IR@curaleaf.com

Media Contact:

MATTIO Communications

MattioCuraleaf@Mattio.com

SOURCE Curaleaf Holdings, Inc.

Share this article

Hisense predstavuje na veľtrhu IFA 2026 koncept „Companion Living" s podporou AI

BERLÍN, 4. september 2026 /PRNewswire/ – Spoločnosť Hisense, popredná globálna značka v oblasti spotrebnej elektroniky a domácich spotrebičov, predstavuje na veľtrhu IFA 2026 svoju víziu „Companion Living" (Spoločené bývanie) v duchu témy „Innovating a Brighter Life" (Inovácie pre jasnejší život), pričom prostredníctvom svojich riešení V AIOS a AI Companion Suite prináša AI do každodenných činností.

Jadrom systému je V AIOS, ďalší vývojový stupeň operačného systému VIDAA, postavený na štyroch kľúčových schopnostiach AI: Vnímať, rozmýšľať, komunikovať a konať. Vďaka nim môže systém V AIOS vnímať ľudí, zariadenia a ich okolie, rozumieť kontextu a zámeru, prirodzene komunikovať medzi viacerými ľuďmi a zariadeniami a koordinovať obsah, zariadenia a služby tak, aby konali v mene používateľa. Výsledkom je intuitívnejší základ pre inteligentný život zameraný na človeka.

Na základe umelej inteligencie prináša AI Companion Suite inteligenciu do troch oblastí každodenného života: Varenie, pranie a vzduchotechnika a energia. V kuchyni sa inteligencia prepája v celom priestore, aby varenie prebiehalo bez námahy. Pochopením individuálnych preferencií v oblasti stravovania, dostupných surovín a kontextu môže kuchyňa koordinovať chladničku, rúru a ďalšie spotrebiče, aby vám odporučila, čo pripraviť, a usmernila proces varenia – z toho, čo máte v chladničke sa tak stane večera pripravená pre vás na mieru.

V praní bielizne tá istá inteligencia pomáha eliminovať dohady o tom, ako sa starať o odevy, rozpoznáva tkaniny a koordinuje pranie a sušenie podľa konkrétnych požiadaviek na ošetrovanie jednotlivých kusov bielizne. V obytnom priestore slúži UR9 ako brána do prepojeného domu, spája pohodlie a riadenie energie s cieľom prispôsobiť prúdenie vzduchu a domáce prostredie ľuďom a podmienkam.

Tieto inovácie spoločne demonštrujú, ako sa AI môže posunúť za hranice jednotlivých inteligentných zariadení a stať sa proaktívnejšou, osobnejšou a bezproblémovou súčasťou každodenného života.

Okrem oblasti domácnosti oznámila spoločnosť Hisense aj partnerstvo s UEFA EURO 2028, čo je už štvrté partnerstvo s turnajom majstrovstiev Európy UEFA po sebe, konkrétne po spolupráci na turnajoch v rokoch 2016, 2020 a 2024. Od každodenného života až po globálne športové momenty, Hisense naďalej oživuje svoju víziu „Inovácie pre jasnejší život" prostredníctvom technológií, ktoré zbližujú ľudí.

O spoločnosti Hisense

Spoločnosť Hisense, založená v roku 1969, je celosvetovo uznávaným lídrom v oblasti domácich spotrebičov a spotrebnej elektroniky, ktorý pôsobí vo viac ako 180 krajinách a špecializuje sa na poskytovanie vysokokvalitných multimediálnych produktov, domácich spotrebičov a inteligentných IT riešení. Podľa spoločnosti Omdia je Hisense celosvetovo jednotkou v segmente televízorov s uhlopriečkou 100 palcov a viac (rok 2023 – 1. polrok 2026). Spoločnosť Hisense je priekopníkom technológie RGB MiniLED a naďalej stojí na čele inovácií v oblasti RGB MiniLED novej generácie. Ako oficiálny sponzor Majstrovstiev sveta vo futbale FIFA World Cup 2026TM sa Hisense angažuje v globálnych športových partnerstvách, ktoré sú spôsobom, ako sa spojiť s publikom na celom svete.

Share this article

Hisense prezentuje na targach IFA 2026 koncepcję „Companion Living" opartą na AI

BERLIN, 4 września 2026 r. /PRNewswire/ -- Hisense, jedna z wiodących światowych marek elektroniki użytkowej i sprzętu AGD, prezentuje podczas targów IFA 2026 swoją wizję „Companion Living" pod hasłem „Innovating a Brighter Life", pokazując, jak dzięki V AIOS i pakietowi AI Companion Suite sztuczna inteligencja może wspierać użytkowników w codziennym życiu.

Centralnym elementem jest V AIOS - nowa generacja systemu VIDAA OS, oparta na czterech kluczowych funkcjach AI: Wykrywanie, analizowanie, komunikowanie się i działanie. Dzięki tym funkcjom V AIOS rozpoznaje użytkowników, urządzenia i ich otoczenie, rozumie kontekst oraz intencje, umożliwia naturalną komunikację między użytkownikami i urządzeniami, a także koordynuje treści, urządzenia i usługi, aby wykonywać określone działania w imieniu użytkownika. W efekcie powstaje bardziej intuicyjna i skoncentrowana na użytkowniku podstawa inteligentnego stylu życia.

Na tej podstawie AI Companion Suite wykorzystuje możliwości AI w trzech obszarach codziennego życia: Gotowanie, pranie oraz jakość powietrza i energia. W kuchni inteligentne rozwiązania współpracują ze sobą, sprawiając, że gotowanie staje się prostsze i bardziej intuicyjne. Uwzględniając indywidualne preferencje żywieniowe, dostępne składniki i bieżący kontekst, system może koordynować pracę lodówki, piekarnika i innych urządzeń, podpowiadać, co przygotować, oraz prowadzić użytkownika krok po kroku przez proces gotowania - tak, aby z dostępnych produktów powstał posiłek dopasowany do jego potrzeb.

W przypadku prania ta sama inteligentna technologia ułatwia właściwą pielęgnację odzieży, rozpoznając rodzaj tkaniny oraz odpowiednio dobierając parametry prania i suszenia do poszczególnych ubrań. W przestrzeni mieszkalnej UR9 pełni rolę centrum połączonego domu, łącząc funkcje związane z komfortem i zarządzaniem energią oraz dostosowując przepływ powietrza i warunki w pomieszczeniach do potrzeb użytkowników i aktualnej sytuacji.

Wszystkie te innowacje pokazują, jak AI może wyjść poza ramy pojedynczych inteligentnych urządzeń i stać się bardziej proaktywnym, spersonalizowanym i intuicyjnym elementem codziennego życia.

Poza rozwiązaniami dla domu Hisense ogłosił również partnerstwo z UEFA EURO 2028. Będzie to już czwarta z rzędu edycja Mistrzostw Europy UEFA, przy której marka współpracuje, po turniejach w 2016, 2020 i 2024 roku. Zarówno w codziennym życiu, jak i podczas największych wydarzeń sportowych na świecie Hisense konsekwentnie realizuje swoją wizję „Innovating a Brighter Life", wykorzystując technologie, które zbliżają ludzi.

Hisense

Firma Hisense, założona w 1969 r., jest liderem światowego rynku urządzeń RTV/AGD i elektroniki użytkowej, z oddziałami w ponad 180 państwach. Hisense specjalizuje się w wysokiej klasy produktach multimedialnych, urządzeniach dla domu i inteligentnych rozwiązaniach IT. W rankingu firmy analitycznej Omdia firma Hisense zajmuje pozycję lidera w segmencie telewizorów 100-calowych i większych (okres 2023 – 1. półrocze 2026). Firma Hisense, jako twórca technologii RGB MiniLED, wprowadza dalsze innowacje w zakresie telewizorów RGB MiniLED nowej generacji. Jako oficjalny sponsor Mistrzostw Świata w Piłce Nożnej FIFA World Cup 2026™ Hisense konsekwentnie stawia na współpracę ze światem sportu, by docierać do odbiorców na całym globie.

Share this article

First-ever Flying Eye Hospital training project in Macau, supported by Alcon and OMEGA, highlights two decades of local support advancing eye health in China and around the world.

MACAU, Sept. 4, 2026 /PRNewswire/ -- Global eye care nonprofit Orbis International is celebrating 20 years of partnership with the Macau community with the arrival of its Flying Eye Hospital for the first-ever simulation-based training project in Macau. The project will engage 70 ophthalmologists and nurses from eight Orbis partner hospitals across China to Macau for advanced training and mentorship aboard the Flying Eye Hospital and at Kiang Wu Nursing College of Macau. Together, these professionals will go on to serve more than 245,000 patients in China annually.

This project, locally supported by the Civil Aviation Authority, the Health Bureau of the Macau Special Administrative Region, and many dedicated local and international supporters, will serve as a platform for hands-on training, innovation, and knowledge exchange. Training will focus on simulated cataract, glaucoma, strabismus, medical retina, and nursing specialties, strengthening participants' skills, which they can apply throughout their careers and share with future generations of eye care professionals.

Since Orbis Macau was established in 2006, the Macau community has raised more than US$33 million to support Orbis's work in China and around the world. As a bridge between Macau's supporters and Orbis's global mission, Orbis Macau has mobilized donors, companies, schools, foundations and volunteers to help strengthen eye care systems, train health professionals and expand access to quality eye care.

"For twenty years, the people of Macau have stood beside Orbis as partners in our mission," said Isabel da Silva, Director of Development, Orbis Macau. "The real story of this visit is not just the aircraft. It's the thousands of individuals, companies, schools, and volunteers of Macau who have supported Orbis over the last two decades. Their generosity has helped make sight-saving work possible around the world, and this project offers a unique opportunity for the Macau community and our supporters to see the impact of their contributions firsthand. By supporting Orbis's global work, they are directly helping to empower eye care teams in China to safeguard eye health in rural and remote communities, while also advancing efforts to raise awareness of eye health locally in Macau."

Cybersight, Orbis's telemedicine and e-learning platform, is an integral part of every Flying Eye Hospital project—connecting in-person training with continuous learning before and after the aircraft is on site. Through Cybersight, participants can prepare in advance, consult with global experts, access ongoing education, and continue building skills long after the project concludes, extending the impact of the Flying Eye Hospital far beyond the aircraft itself.

"For 20 years, the Macau community has helped Orbis turn generosity into lasting impact," said Kathleen Sherwin, President and CEO of Orbis International. "This project shows what that looks like in practice. By bringing eye care teams from across China together for advanced simulation training and connecting them to ongoing mentorship through Cybersight, we are investing not only in individual clinicians, but in stronger eye care systems. The knowledge gained here will travel back with these doctors and nurses to the communities they serve and continue multiplying for years to come."

Alcon has been a generous supporter of Orbis for more than 45 years, providing financial support to the Flying Eye Hospital through the Alcon Foundation, as well as donations of state-of-the-art ophthalmic equipment, surgical products, and supplies through Alcon Cares.

"Alcon is proud to support Orbis's first Flying Eye Hospital training project in Macau, a milestone that reflects both the strength of our more than 45-year collaboration with Orbis, and Macau's remarkable commitment to advancing eye health," said Melisa Chong, Surgical Franchise Head, Alcon Hong Kong. "Helping people see brilliantly is our purpose, and we know that building local capacity is one of the most effective ways to create lasting impact. By equipping ophthalmologists and nurses with advanced training, technology and ongoing educational resources, this program will help strengthen eye care capacity in China and expand access to quality eye care in underserved communities. Together with Orbis and the people of Macau, we are helping create a future where more patients can receive the eye care they need to see their world more clearly."

Since 2011, OMEGA has proudly supported Flying Eye Hospital projects and works in cooperation with its celebrity brand ambassadors to increase awareness of Orbis and its mission. OMEGA also provides teddy bears to all young patients being treated on the plane.

"By dedicating their time over 20 years, Orbis has created a true legacy of excellence in Macau. OMEGA is proud to be part of this long-standing community initiative. These 20 years are a testament to the commitment, innovation, and passion that we so deeply admire in Orbis.", President & CEO of OMEGA, Raynald Aeschlimann.

The Macau Program is part of Orbis's 2026 annual Flying Eye Hospital global program, and Orbis is deeply grateful that it brings together international sponsors and local partners, including Alcon, OMEGA, the Civil Aviation Authority of Macau Special Administrative Region, and the Health Bureau of the Macau Special Administrative Region. Orbis is also honored for support from Macau International Airport Co. Ltd. (CAM), Menzies Aviation Macau, TAG Aviation Asia (Macau) Ltd., Min Da Construction & Engineering Co. Ltd., Sands China Ltd., MGM, Kiang Wu Nursing College of Macau, CSI Group Macau, Macau Coca-Cola Beverage Co. Ltd FedEx, Woodward Inc., AirAsia, Embraer, and GE Aerospace. Together, these supporters are making the first simulation training project in Macau possible. By bringing eye care teams from Orbis partner hospitals across China to train in the city, the project directly contributes to strengthening long-term eye care in rural and remote Chinese communities.

About Orbis Macau

For twenty years, Orbis Macau has built a strong network of support among donors, companies, foundations, schools, volunteers, and community partners across Macau. Through fundraising, partnership building, public awareness campaigns, educational outreach, and volunteer engagement, Orbis Macau serves as an important bridge between the local community and Orbis's global sight-saving work. The impact of that support can be seen in stronger eye care systems, better-trained health professionals, expanded access to services, and innovations that help reach communities where specialized eye care is often difficult to access.

About Orbis International

Orbis International is a global eye care nonprofit working to prevent avoidable blindness and restore sight in communities where access to eye care is limited. Through the Flying Eye Hospital, Cybersight, and long-term partnerships with local hospitals and clinics, Orbis trains eye care teams, strengthens health systems, and helps people access the care they need. Orbis ranks in the top 3% of U.S. charities, having earned top marks for transparency and accountability from Charity Navigator, GuideStar, and the Better Business Bureau. To learn more, please visit orbis.org.

About Alcon

Alcon helps people see brilliantly. As the global leader in eye care with a heritage spanning over 75 years, we offer the broadest portfolio of products to enhance sight and improve people's lives. Our Surgical and Vision Care products touch the lives of people in over 140 countries and territories each year living with conditions like cataracts, glaucoma, retinal diseases and refractive errors. Our more than 25,000 associates are enhancing the quality of life through innovative products, partnerships with Eye Care Professionals and programs that advance access to quality eye care. Learn more at www.alcon.com.

About OMEGA

OMEGA is a prestigious Swiss watchmaker and member of the Swatch Group Ltd. Since 1848, the brand has been synonymous with excellence, innovation and precision, as well as a pioneering spirit, demonstrated by conquests of the oceans and space. In fact, since 1965, the OMEGA Speedmaster has been worn on each of NASA's manned missions including all six moon landings. As well as this, no brand is more actively involved in sports timekeeping. In addition to partnerships in golf, sailing, athletics and swimming, OMEGA has served as the Official Timekeeper for the Olympic Games since 1932 and the Paralympic Games since 1992. Most importantly, OMEGA has a tradition of excellence in watchmaking. This reputation was reinforced in 2015 with the introduction of METAS-approved Master Chronometer certification, representing the Swiss industry's highest standard of precision, magnetic resistance and performance.

Media Contacts

Orbis International

Jenna Montgomery

Associate Director, Global Communications and Marketing

Jenna.montgomery@orbis.org

Alcon

Steven Smith

+ 41 589 112 111 (Geneva)

+ 1 817 551 8057 (Fort Worth)

globalmedia.relations@alcon.com

OMEGA

OMEGA International Press Office

Rue Jakob-Stämpfli 96 – 2502 Biel/Bienne - Switzerland

Tel. +41 32 343 9211

press@omega.ch

www.omegawatches.com

SOURCE Orbis International

Share this article

ARD Mediathek - Die Highlights im Oktober 2026

München (ots)

Breitscheidplatz 19/12

Mini-Serie (6 x 45 Min.)

Ab 30. Oktober 2026

2015: NRW-Staatsschützer Laudin nutzt den Ex-Kriminellen Murat Cem als Informanten im IS-Milieu. Cem warnt vor Anis Amri, doch Behörden unterschätzen ihn - bis zum Anschlag in Berlin.

House of Yang

Mystery-Serie (6 x 30 Min.)

Ab 9. Oktober 2026

Zwei Mädchen verschwinden aus einem Haus. Das erste 1949, das zweite 1999. Beide tauchen nie wieder auf. Als Jessie (Elisa Hofmann) das Haus erbt, begreift zu sie spät, welche Gefahr darin lauert.

Das Vergessen - Spurlos im Moor

Mini-Serie (6 x 45 Min.)

Ab 23. Oktober 2026

Eine Polizistin jagt den Mörder ihrer Nichte. Doch schon bald wird die Suche nach der Wahrheit zu einem Wettlauf gegen die Zeit. Ein packender Thriller, in dem nichts so ist, wie es scheint.

Sommer auf Asphalt

Spielfilm (90 Min.)

Ab 2. Oktober 2026

Fahrradkurierin Les lebt chaotisch zwischen Lieferjobs und Partys. Eine ungeplante Schwangerschaft, ihre Affäre Roya und der kranke Vater Bert bringen ihr Leben völlig durcheinander.

Y-Kollektiv

Reportagen (20-45 Min.)

Immer montags

Y-History: Aussortiert im Schulsystem? | Jung, todkrank, aber lebendig | Hikikomori - die einsamsten Menschen der Welt | Tödliches Gold (AT)

team.recherche: Diagnose Machtmissbrauch (AT)

Investigative Doku (30 Min.)

Ab 6. Oktober 2026

Viele Ärztinnen berichten, dass trotz Leistung männliche Chefärzte über ihre Karriere entscheiden: Wer operiert, befördert wird oder stehen bleibt. Die Recherche zeigt, wie groß diese Macht ist und was sie für Frauen bedeutet.

Staatsgeheimnis RAF - Terroristen in der DDR

Dokumentation (90 Min.)

Ab 7. Oktober 2026

Die DDR gewährte in den 1980er Jahren zehn Top-Terroristen Unterschlupf. Die Staatssicherheit gab den RAF-Aussteigern eine neue Identität, ein neues Leben. Während blutige Attentate die Bundesrepublik erschütterten - und Ermittler fieberhaft nach der RAF fahndeten - versuchten die Aussteiger, in der DDR ein bürgerliches und unauffälliges Dasein zu führen.

Seelenfänger. Der falsche Heiler

Doku-Serie (2 x 30 Min.)

Ab 13. Oktober 2026

Wenn Heilsversprechen zur Gefahr werden: Die investigative Doku-Serie "Seelenfänger: Der falsche Heiler" erzählt von Menschen, die Angehörige verloren haben, weil diese an die Lehren der sogenannten "Germanischen Neuen Medizin" geglaubt haben.

No Angels - Das sind wir

Doku-Serie (3 x 30 Min.)

Ab 14. Oktober 2026

25 Jahre nach "Popstars" erzählen die No Angels ihre Geschichte neu: ehrlich, exklusiv und überraschend persönlich. Die dreiteilige Doku-Reihe "No Angels - Das sind wir" beleuchtet Deutschlands erste Castingband und zeigt, wie aus Teenie-Idolen selbstbestimmte Frauen wurden.

KSK - Geheime Krieger: Die geheime Welt der deutschen Elite-Soldaten

Dokumentarfilm (90 Min.)

Ab 15. Oktober 2026

30 Jahre KSK: Ehemalige Kommandosoldaten gewähren exklusive Einblicke in das Innerste dieser Elitetruppe, ihre Einsätze, ihren Alltag und ihre schwerste Krise.

Sonne und Beton

Spielfilm (120 Min.)

Ab 17. Oktober 2026

Preisgekrönte Coming-of-Age-Geschichte im Hitzesommer 2023 von Regisseur David Wendt und Autor Felix Lobrecht.

Falsch, aber anders lustig

Comedy-Show (6 x 30 Min.)

Ab 17. Oktober 2026

Die Impro-Comedy-Show ist mit sechs neuen Folgen in der ARD Mediathek zurück. Moritz Neumeier lädt Comedians und Influencer:innen zu absurden Spielen mit herrlich falschen Antworten ein.

Motsi & Oti. Meet the Mabuses

Doku-Soap (6 x 30 Min.)

Ab 19. Oktober 2026

Motsi und Oti Mabuse gewähren erstmals private Einblicke in ihr echtes, authentisches (Familien-) Leben. Sie öffnen die Türen zu ihrer Welt: bunt, laut, voller Lebensfreude- aber vor allem emotional und zutiefst persönlich.

ARD Crime Time: Der Fall Josephine R. Eine Familie am Abgrund.

True-Crime-Reihe (3 x 30 Min.)

Ab 20. Oktober 2026

Eine junge Frau beschuldigt ihre Eltern des Missbrauchs, sie werden zu langen Haftstrafen verurteilt. Später zeigen Widersprüche und Ermittlerzweifel: Möglicherweise sitzen sie zu Unrecht. ARD Crime Time erzählt ihren Fall.

Die Carolin Kebekus Show

Comedy-Show (7 x 30.Min.)

Ab 22. Oktober 2026

"Die Carolin Kebekus Show" kehrt ab 22. Oktober 2026 mit sieben neuen Folgen in ARD Mediathek und Erstem zurück: Stand-up, Musik, Sketche und Aktionen mit Gästen wie Motsi Mabuse, Bastian Pastewka und Mai Thi Nguyen-Kim.

Weltspiegel Doku: Halbzeit für Trump: Dämpfer oder Machterhalt?

Dokumentation (45 Min.)

Ab 23. Oktober 2026

ARD-Korrespondentin Gudrun Engel reist vor den anstehenden Midterms kreuz und quer durchs Land - wie fühlt es sich an, für die Amerikaner - zwei Jahre unter Trump? Beurteilen sie seine Arbeit an den Wahlurnen mit?

Blood Cruise - Vampire an Bord

Thriller/Horror-Serie (6 x 55 Min.)

Ab 23. Oktober 2026

Auf einer Nachtfähre nach Helsinki entfesselt ein "Blinder Passagier" einen blutigen Vampir-Horrortrip. In sechs Folgen kämpft ein Ensemble aus britischen und skandinavischen Stars ums Überleben auf hoher See.

History or Mystery - Die Burgenchallenge mit Alexander Prinz

Infotainment (3 x 30 Min.)

Ab 24. Oktober 2026

Eine Burg, zwei Besucher und drei mittelalterliche Geschichten - aber nur eine davon ist wahr. Alexander Prinz, auf Youtube bekannt als der "Dunkle Parabelritter" führt im neuen ARD Mediatheksformat "History or Mystery" prominente Gäste durch Festungen verschiedener Regionen. Mit dabei: Schauspielerin Davina Fox, Sternekoch Robin Pietsch und Comedian Tony Bauer.

team.recherche: Sog der Sekten (AT)

Dokumentation (30 Min.)

Ab 27. Oktober 2026

team.recherche taucht ein in die Welt sektenähnlicher Gruppierungen, recherchiert undercover und erzählt die Geschichte einer jungen Frau, die den Druck ihrer Gruppe nicht mehr aushielt.

Meine Träume - Was verraten sie über mich?

Wissens-Doku (45 Min.)

Ab 29. Oktober 2026

Was sagen Träume über uns aus? Sind wir belastenden Träumen hilflos ausgeliefert? Und können wir Träume eventuell sogar aktiv gestalten? Die Dokumentation begleitet drei Menschen dabei, ihre Träume besser zu verstehen.

Pressedossier mit ausführlichen Informationen zu den Highlights in der ARD Mediathek: https://pressekits.ard.de/highlights-ard-mediathek

Pressekontakt:

Ingrid Günther

ARD-Programmdirektion/Presse und Information

E-Mail: presse.daserste@ard.de

Fotos bei ard-foto.de und br-foto.de

Weitere Informationen sowie Ansichtsfolgen zu vielen Formaten finden Sie im ARD Presseservice: programmpresse.ard.de

Original-Content von: ARD Mediathek, übermittelt durch news aktuell

DIMERIX SECURES A$34 MILLION NON-DILUTIVE FACILITY TO FUND KEY CLINICAL MILESTONES

- Dimerix successfully enters into non-dilutive facility agreements to access A$34 million[1] with a syndicate of Australian and U.S. independent lenders, including the previously announced initial facility of A$10 million[2]

- Facility terms for all Lenders substantially consistent with the previously announced loan facility;[2] with minor amendments made to the SKIPTAN agreement to standardise key terms across all Lenders (other than in respect of security, refer to Appendix 1)

- Dimerix has elected to drawdown only 50% of the amount committed initially, which is considered sufficient to complete all currently planned activities, including delivery of the ACTION3 Phase 3 trial of DMX-200 and continued advancement of the Phase 2 trial of DMX-652 in Acute Kidney Injury[3]

- The facility provides the option to secure up to A$50m in total commitments on or before 31 March 2027, should Dimerix elect to do so; noting the Company currently has no plans access this additional funding

- Facility provides Dimerix with considerable financial flexibility without diluting shareholders

MELBOURNE, Australia, Sept. 4, 2026 /PRNewswire/ -- Dimerix Limited (ASX: DXB, "Dimerix") a clinical-stage biopharmaceutical company developing kidney disease treatments, is pleased to announce that it has successfully secured non-dilutive loan facility agreements ("Loan Agreements") with a group of Australian and U.S. based lenders to access up to A$34 million[1] (see key terms in Appendix 1), including the existing A$10 million facility agreement with SKIPTAN.[2]

"We are delighted with the support received from lenders across both Australia and the United States, reflecting growing confidence in Dimerix, our clinical programs and our mission to improve outcomes for patients suffering from serious kidney diseases. The successful entry into this facility provides Dimerix with the financial flexibility needed to execute our planned development activities without dilution for shareholders.

Importantly, we have taken a disciplined approach and elected to access only the funding considered required to complete our currently planned activities. We believe this is in the best interests of shareholders, including completion of both the ACTION3 Phase 3 trial of DMX-200 and the Phase 2 trial of DMX-652 in Acute Kidney Injury.

Kidney disease is now recognised as one of the fastest-growing causes of death globally, and yet treatment options remain limited for many patients. As a company dedicated exclusively to kidney disease, Dimerix remains focused on developing new treatment options that have the potential to improve and extend the lives of patients in urgent need."

Dr Nina Webster, CEO & Managing Director, Dimerix

Non-dilutive funding flexibility

The facility has been established to support Dimerix's ongoing clinical development programs and provides the Company with significant financial flexibility while advancing its late-stage pipeline.

The terms of the facility for the new lenders are substantially similar to those previously announced for the SKIPTAN facility (ASX: 17 July 2026), with SKIPTAN terms amended to ensure alignment (see Appendix 1 for details). The facility provides the flexibility for Dimerix to elect to take further commitments for up to a total of A$50m on or before 31 March 2027.

Importantly, Dimerix has elected to initially drawdown only the amount of funding considered required to complete its currently planned activities, being 50% of the currently committed funds.[3] This disciplined approach to capital management minimises financing costs and shareholder dilution, while maintaining the flexibility to access additional capital under the facility if required in the future.

Funded for ACTION3 trial and DMX-652 development activities

Based on the Company's present operating plans and anticipated expenditure, Dimerix confirms that it is funded through to completion of the ACTION3 Phase 3 trial in DMX-200, as well as the planned Phase 2 clinical trial in DMX-652, through:[3]

- Existing cash reserves; and

- A$34 million[1] via the binding Loan Agreements, with receipt of the initial 50% draw-down anticipated in September 2026 and the remainder to take place at the Company's discretion on or before 31 March 2027.

The facility is anticipated to be repaid through existing future licensee milestone payment(s), potential new license fees and/or capital market access. Dimerix has secured five commercial partners across major markets, generating A$81 million in upfront payments received to date and creating the opportunity for a further A$237 million in development milestone payments ahead of commercial launch.[4]

Advancing a Leading Kidney Disease Pipeline

Kidney disease is among the fastest-growing causes of death worldwide and represents a significant and increasing healthcare burden. Despite this growing prevalence, many forms of kidney disease continue to have limited treatment options available for patients.[5],[6]

Dimerix is uniquely focused on kidney diseases, with a pipeline designed to address significant unmet medical needs. The Company's lead program, DMX-200, is currently being evaluated in the fully recruited global ACTION3 Phase 3 clinical trial in patients with FSGS - a serious, rare kidney disease that can lead to kidney failure and the need for dialysis or transplantation.

Dimerix is also advancing DMX-652 for Acute Kidney Injury, a condition associated with significant morbidity, mortality and healthcare costs worldwide. The Phase 2 clinical program is designed to evaluate the potential of DMX-652 in preventing kidney injury and preserving renal function, following cardiac surgery.

Potential catalysts

As Dimerix advances its pivotal, fully recruited ACTION3 Phase 3 trial for DMX-200 toward what is anticipated to be a major value-creating event if successful, the Company has simultaneously strengthened its growth profile through the recent acquisition of DMX-652 and its ongoing advancement into Phase 2 clinical development. Progress and positive outcomes from the DMX-652 development program have the potential to create substantial additional shareholder value, diversify Dimerix's clinical pipeline, and deliver multiple near- and medium-term catalysts for investors.

The entry into the A$34 million[1] facility the subject of the Loan Agreements is expected to support these important clinical milestones and further strengthen Dimerix's position as a leading kidney disease-focused biotechnology company.

Authorised for lodgement by the Board of Dimerix

—END—

For further information, please visit our website at www.dimerix.com.

Follow Dimerix on LinkedIn and X

About Dimerix

Dimerix Limited (ASX: DXB) is a clinical-stage biopharmaceutical company focused on developing new therapies for kidney diseases with significant unmet medical need. The Company's lead program, DMX-200, is currently in Phase 3 clinical development for focal segmental glomerulosclerosis (FSGS), a serious and life-threatening rare kidney disease with limited treatment options. In addition, Dimerix is advancing a Phase 2 program in acute kidney injury (AKI), further strengthening its pipeline in high-need renal indications. With a growing network of five commercial partners supporting global development and future market access, Dimerix is committed to expanding its reach and delivering innovative treatments to as many patients as possible worldwide while creating long-term value for shareholders. For more information, please visit the company's website at www.dimerix.com.

About DMX-200 in FSGS

FSGS is a rare, serious kidney disorder characterised by progressive scarring (sclerosis) in parts of the glomeruli - the kidney's filtering units. This scarring leads to proteinuria, progressive loss of kidney function, and often end-stage renal disease. FSGS is increasingly understood to have an inflammatory component, with monocyte and macrophage activation contributing to glomerular injury. In the United States, more than 40,000 people are estimated to be living with FSGS, including both adults and children.[7] There are no therapies specifically approved for FSGS in the U.S., and disease management relies on non-specific immunosuppressive and supportive therapies. In patients with progressive or treatment-resistant FSGS, the average time from diagnosis to end-stage kidney disease can be as short as five years. Even among those who undergo kidney transplantation, disease recurrence occurs in up to 60% of cases,[8] underscoring the urgent need for new, disease-modifying treatments.

DMX-200 is a chemokine receptor (CCR2) antagonist administered to patients already receiving an angiotensin II type I receptor (AT1R) blocker, the standard of care treatment for hypertension and kidney disease. DMX-200 is protected by granted patents in various territories until 2032, with patent applications submitted globally that may extend patent protection to 2042, in addition to Orphan Drug Designation granted in the United States, Europe, UK and Japan[9].

About DMX-652 in Acute Kidney Injury

Acute kidney injury (AKI) is a prevalent and severe clinical syndrome of substantial unmet need. It can arise from several high-risk clinical settings including, most notably, cardiac surgery and sepsis and is characterised by a rapid decline in kidney function (within hours), often resulting in high morbidity and mortality. The current addressable patient population is estimated to be approximately 260,000 across the major markets of United States, Germany, France, Italy, Spain and United Kingdom per annum,[10],[11] making this indication a potential orphan designation. AKI represents a significant clinical burden. There are no approved therapies for AKI, which is associated with rapid kidney function decline within hours, increased risk of chronic kidney disease and long-term kidney complications.

Acepodia Announces FDA Clearance of IND Application for ACE723, a Novel Dual-Payload Antibody-Drug Conjugate

FDA clearance enables initiation of a Phase 1 clinical trial and advances the first AD2C-generated candidate into clinical development

ALAMEDA, Calif. and TAIPEI, Sept. 4, 2026 /PRNewswire/ -- Acepodia (6976: TT), a clinical-stage biotechnology company developing next-generation cell therapies and antibody-drug conjugates, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug (IND) application for ACE723, a GPC3-targeted dual-payload antibody-drug conjugate (ADC) developed using Acepodia's proprietary Antibody-Dual-Drugs Conjugation (AD2C) platform for the treatment of unresectable or metastatic hepatocellular carcinoma (HCC). The clearance enables Acepodia to advance ACE723 into Phase 1 clinical development.

"The FDA clearance of ACE723 marks an important milestone for our AD2C platform and brings our first AD2C-generated candidate into clinical development," said Sonny Hsiao, Ph.D., Chief Executive Officer and Chairman of Acepodia. "ACE723 is designed to deliver two cytotoxic payloads to GPC3-expressing tumor cells, with the goal of addressing tumor heterogeneity and potential resistance to single-payload therapies. We look forward to evaluating its safety, pharmacokinetics and preliminary anti-tumor activity in patients with unresectable or metastatic HCC."

ACE723 is an investigational GPC3-targeted dual-payload ADC developed through Acepodia's proprietary AD2C platform, which integrates expertise in antibody engineering, medicinal chemistry and tumor biology. GPC3 is a tumor-associated antigen frequently expressed in HCC, providing a potential target for selective delivery of cytotoxic payloads to tumor cells.

HCC accounts for more than 70% of liver cancer cases worldwide. Although immunotherapy-based combination regimens have improved first-line treatment for patients with unresectable or metastatic disease, significant unmet medical need remains for patients whose disease progresses or becomes resistant to treatment, underscoring the need for therapies with differentiated mechanisms of action.

The planned Phase 1 study will evaluate the safety, tolerability, dose-limiting toxicities, pharmacokinetics and preliminary anti-tumor activity of ACE723 in patients with unresectable or metastatic HCC. The dose-escalation portion of the study is expected to characterize the safety profile and establish a recommended dose for subsequent clinical development and potential expansion cohorts.

Acepodia also submitted an IND application for ACE723 to China's National Medical Products Administration (NMPA) in August 2026 as part of the Company's global development strategy for the program.

About Acepodia

Acepodia (6976: TT) is a clinical-stage biotechnology company developing next-generation therapies for cancer and autoimmune diseases through its proprietary conjugation technology platforms. Leveraging a family of bio-orthogonal click chemistry approaches originating from Nobel Prize laureate Carolyn Bertozzi's laboratory, Acepodia has built a modular platform designed to combine antibodies with immune cells or therapeutic payloads to create differentiated treatment modalities.

The Company is advancing a pipeline based on its Antibody-Cell Conjugation (ACC) and Antibody-Dual-Drugs Conjugation (AD2C) platforms. These technologies are designed to enable flexible integration across antibodies, immune cells, and payload architectures, with the goal of enhancing targeted therapeutic activity while supporting broad applicability across hematologic malignancies, solid tumors, and autoimmune diseases.

By applying its conjugation technologies across multiple therapeutic modalities, Acepodia aims to develop scalable and differentiated therapies for patients with significant unmet medical needs.

For more information, please visit www.acepodia.com.

SOURCE Acepodia, Inc.

Share this article

CLEVELAND, Sept. 4, 2026 /PRNewswire/ -- KeyCorp (NYSE: KEY) announced today that Clark Khayat, Chief Financial Officer, will present at the Barclays Global Financial Services Conference on Monday, September 14, 2026, at 2:45 p.m. ET.

KeyCorp plans to review its performance, strategy, and outlook, and the discussion may include forward-looking statements and other material information. The live audio webcast will be available on the day of the conference at www.key.com/ir. If you are unable to join the live webcast, or wish to hear a re-broadcast, access www.key.com/ir and select Events & Presentations.

ABOUT KEYCORP

KeyCorp's roots trace back more than 200 years to Albany, New York. Headquartered in Cleveland, Ohio, Key is one of the nation's largest bank-based financial services companies, with assets of approximately $191 billion at June 30, 2026.

Key provides deposit, lending, cash management, and investment services to individuals and businesses in 15 states under the name KeyBank National Association through a network of approximately 950 branches and approximately 1,100 ATMs. Key also provides a broad range of sophisticated corporate and investment banking products, such as merger and acquisition advice, public and private debt and equity, syndications and derivatives to middle market companies in selected industries throughout the United States under the KeyBanc Capital Markets trade name. For more information, visit https://www.key.com/. KeyBank Member FDIC.

SOURCE KeyCorp

Share this article

BRIDGEWATER, N.J., Sept. 4, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced the granting of inducement awards to 128 new employees. The awards were granted under the Insmed Incorporated 2025 Inducement Plan, which is intended to meet the requirements of a plan providing for inducement grants under Nasdaq Listing Rule 5635(c)(4). The awards were approved by Insmed's Compensation Committee and made as a material inducement to each employee's entry into employment with the Company.

In connection with the commencement of their employment, on August 31, 2026, the employees received 115,320 restricted stock units and options to purchase an aggregate 5,560 shares of Insmed common stock at an exercise price of $121.82 per share, the closing trading price on the Nasdaq Global Select Market on the date of grant.

The restricted stock units have a four-year vesting schedule, with 25% of the shares underlying each restricted stock unit grant vesting on each anniversary of the first day of the month immediately following the grant date, subject to the relevant employee's continued service with Insmed on the applicable vesting date.

The options have a 10-year term and a four-year vesting schedule, with 25% of the shares subject to the option vesting on the first anniversary of the first day of the month immediately following the grant date and 12.5% of the shares subject to the option vesting every six months thereafter through the fourth anniversary thereof, subject to the relevant employee's continued service with Insmed on the applicable vesting date.

About Insmed

Insmed Incorporated is a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases. The Company is advancing a diverse portfolio of approved and mid- to late-stage investigational medicines — including two approved therapies to treat chronic, debilitating lung diseases — as well as cutting-edge drug discovery focused on serving patient communities where the need is greatest. Insmed's commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology & Inflammation, and Neuro & Other Rare. The Company's research engine is advancing a wide range of technologies and modalities, including gene therapy, AI-driven protein engineering, RNA end-joining, and synthetic rescue, in the pursuit of future pipeline candidates.

Headquartered in Bridgewater, New Jersey, Insmed has offices and research locations throughout the United States, Europe, and Japan. Insmed is proud to be recognized as one of the best employers in the biopharmaceutical industry, including spending five consecutive years as the No. 1 Science Top Employer. Visit www.insmed.com to learn more or follow us on LinkedIn, Instagram, YouTube, and X.

Contact:

Investors:

Sara Bonstein

Chief Financial Officer

investor.relations@insmed.com

Media:

Claire Mulhearn

Vice President, Corporate Communications

media@insmed.com 

SOURCE Insmed Incorporated

Share this article